Pictet Asset Management (UK)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-110,267
Closed -$3.74M 1854
2021
Q1
$3.74M Sell
110,267
-109,967
-50% -$3.81M ﹤0.01% 890
2020
Q4
$7M Sell
220,234
-8,100
-4% -$213K 0.01% 741
2020
Q3
$5.86M Buy
228,334
+16,110
+8% +$368K 0.01% 685
2020
Q2
$5.45M Sell
212,224
-23,700
-10% -$480K 0.01% 661
2020
Q1
$3.63M Buy
235,924
+89,100
+61% +$1.94M 0.01% 725
2019
Q4
$5.04M Buy
146,824
+800
+0.5% +$9.6K 0.01% 758
2019
Q3
$1.09M Buy
146,024
+8,500
+6% +$81.5K ﹤0.01% 912
2019
Q2
$1.78M Sell
137,524
-2,576
-2% -$33K ﹤0.01% 875
2019
Q1
$1.71M Buy
140,100
+43,700
+45% +$558K ﹤0.01% 875
2018
Q4
$1.1K Buy
96,400
+21,800
+29% +$352K ﹤0.01% 884
2018
Q3
$1.62M Hold
74,600
﹤0.01% 907
2018
Q2
$1.32M Buy
74,600
+5,100
+7% +$104K ﹤0.01% 824
2018
Q1
$1.46M Buy
+69,500
New +$1.35M ﹤0.01% 816
2017
Q2
Sell
-126,864
Closed -$2.06M 876
2017
Q1
$2.06M Buy
126,864
+3,756
+3% +$54.4K 0.01% 769
2016
Q4
$1.86M Buy
123,108
+15,460
+14% +$218K 0.01% 755
2016
Q3
$1.64M Buy
+107,648
New +$4.35M 0.01% 750

Other funds holding ITCI

Pictet Asset Management (UK)'s ITCI Position: Q2 2021 in Review

Pictet Asset Management (UK) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2021, closing a stake of 110,267 shares — an estimated $3.74M sold.

Pictet Asset Management (UK) first reported a position in ITCI in Q3 2016 and held it in 16 quarters. The position peaked at $7M in Q4 2020. 187 funds tracked by Wall St. Rank hold ITCI as of Q2 2021.

  • Pictet Asset Management (UK) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2021 after selling out during the quarter.
  • Pictet Asset Management (UK) sold 110,267 Intra-Cellular Therapies Inc. shares in Q2 2021, an estimated $3.74M.
  • Pictet Asset Management (UK) first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 16 quarters.
  • Pictet Asset Management (UK)'s Intra-Cellular Therapies Inc. position peaked at $7M in Q4 2020.
  • 187 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.